Sugi Predict

Sugi Predict / Targets / NPM1

NPM1

Nucleophosmin · P06748 · NPM1 on Sugi Atlas →

8,153 patent compounds predicted against NPM1, 6,269 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL520509 SCHEMBL520509 0.85 17/20
SCHEMBL520510 SCHEMBL520510 0.85 17/20
SCHEMBL519762 SCHEMBL519762 0.62 17/20
SCHEMBL520140 SCHEMBL520140 0.88 16/20
SCHEMBL520489 SCHEMBL520489 0.88 16/20
SCHEMBL520490 SCHEMBL520490 0.88 16/20
SCHEMBL520188 SCHEMBL520188 0.86 16/20
SCHEMBL520187 SCHEMBL520187 0.83 16/20
SCHEMBL520109 SCHEMBL520109 0.82 16/20
SCHEMBL520110 SCHEMBL520110 0.79 16/20
SCHEMBL520447 SCHEMBL520447 0.77 16/20
SCHEMBL520139 SCHEMBL520139 0.70 16/20
SCHEMBL520048 SCHEMBL520048 0.65 16/20
SCHEMBL520608 SCHEMBL520608 0.48 16/20
SCHEMBL519542 SCHEMBL519542 1.00 15/20
SCHEMBL519543 SCHEMBL519543 1.00 15/20
SCHEMBL519672 SCHEMBL519672 1.00 15/20
SCHEMBL519673 SCHEMBL519673 1.00 15/20
SCHEMBL519741 SCHEMBL519741 1.00 15/20
SCHEMBL520057 SCHEMBL520057 1.00 15/20

Clinical trials — most relevant to NPM1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation PHASE3COMPLETED
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia PHASE3COMPLETED
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML PHASE3RECRUITING
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation PHASE3RECRUITING
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML PHASE3RECRUITING
CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients PHASE3RECRUITING
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia PHASE2WITHDRAWN
Oral Arsenic Trioxide for NPM1-mutated AML PHASE2UNKNOWN
Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML PHASE2RECRUITING
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma PHASE1/PHASE2RECRUITING
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy PHASE2NOT_YET_RECRUITING
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients PHASE2WITHDRAWN
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia PHASE2UNKNOWN
BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia PHASE1/PHASE2RECRUITING
A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders PHASE1COMPLETED
A Safety Study of SGN-CD33A in AML Patients PHASE1COMPLETED
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid PHASE1UNKNOWN
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias PHASE1RECRUITING
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias PHASE1WITHDRAWN
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML PHASE1RECRUITING
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease PHASE1RECRUITING
A Clinical Study of HMPL-506 in Patients With Hematological Malignancies PHASE1RECRUITING
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias PHASE1RECRUITING
Revumenib in Combination With 7+3 + Midostaurin in AML PHASE1RECRUITING
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome nanCOMPLETED
Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse. nanUNKNOWN
Expanded Access to Ziftomenib nanAVAILABLE
Immunophenotyping and Xist Gene in AML nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a NPM1 binder may also engage these)

ProteinNameSimilarity
Q3T160 — 1.000 Q3T160 →
P16039 — 1.000 P16039 →
Q61937 — 1.000 Q61937 →
P13084 — 1.000 P13084 →
P07222 — 1.000 P07222 →
Q9NLA3 — 1.000 Q9NLA3 →
O42584 — 0.995 O42584 →
P05221 — 0.992 P05221 →
Q8LJS2 — 0.991 Q8LJS2 →
Q1HTZ9 — 0.990 Q1HTZ9 →
Q26486 — 0.990 Q26486 →
O59797 — 0.990 O59797 →
Q93ZG9 — 0.989 Q93ZG9 →
P0CP98 — 0.989 P0CP98 →
Q80W85 — 0.989 Q80W85 →
Q9FVE6 — 0.988 Q9FVE6 →
Q1HTZ8 — 0.988 Q1HTZ8 →
Q6IMY8 — 0.988 Q6IMY8 →
P54658 — 0.988 P54658 →
A0A286Y9D1 — 0.988 A0A286Y9D1 →
Q8VEK3 — 0.988 Q8VEK3 →
Q9VXK6 — 0.987 Q9VXK6 →
Q9VTE6 — 0.987 Q9VTE6 →
P0CP99 — 0.987 P0CP99 →
Q8BHX3 — 0.987 Q8BHX3 →
Q56WH4 — 0.986 Q56WH4 →
B8B2R4 — 0.986 B8B2R4 →
Q6DD45 — 0.986 Q6DD45 →
Q9M4T3 — 0.986 Q9M4T3 →
Q27974 — 0.986 Q27974 →